Mesenchymal stem cell (MSC)-based cell therapy has been demonstrated as a promising strategy in the treatment of inflammatory bowel disease (IBD), which is considered an immune disease. While the exact mechanisms underlying the therapeutic effect of MSCs are still unclear, MSCs display anti-inflammatory and immunomodulatory effects by interacting with various immunoregulatory cells. Our previous studies have shown that MSCs can be preconditioned and deconditioned with enhanced cell survival, differentiation and migration. In this study, we evaluated the effect of preconditioning on the immunoregulatory function of human umbilical cord-derived MSCs (hUCMSCs) and their therapeutic effect on treating IBD. Our results show that intraperitoneal administration of deconditioned hUCMSCs (De-hUCMSCs) reduces the disease activity index (DAI), histological colitis score and destruction of the epithelial barrier, and increases the body weight recovery more intensively than that of un-manipulated hUCMSCs. In addition, De-hUCMSCs but not hUCMSCs elicit anti-apoptotic effects via induction of the ERK pathway during the early stage of IBD development. In vitro co-culture studies indicate that De-hUCMSCs suppress T-cell proliferation and activation more markedly than hUCMSCs. Moreover, De-hUCMSCs block the induction of inflammatory cytokines such as tumor necrosis factor (TNF)a and interleukin (IL)-2, while promoting the secretion of the anti-inflammatory cytokine IL-10 in T-cells. Mechanically, we find that prostaglandin E2 (PGE2) secretion is significantly increased in De-hUCMSCs, the suppression of which dramatically abrogates the inhibitory effect of De-hUCMSCs on T-cell activation, implying that the crosstalk between De-hUCMSCs and T-cells is mediated by PGE2. Together, we have demonstrated that preconditioning enhances the immunosuppressive and therapeutic effects of hUCMSCs on treating IBD via increased secretion of PGE2.
Introduction
Inflammatory bowel disease (IBD) is a group of diseases featured by a chronic, relapsing or remitting course of gastrointestinal (GI) symptoms such as diarrhea, rectal bleeding and abdominal cramping 1 . According to the clinical manifestations and pathological traits, IBD is classified as ulcerative colitis (UC) and Crohn's disease (CD). Histologically, UC is mainly restricted in the mucosal layer of colon in a continuous fashion, whereas CD is more featured by discontinuous and ulcerous trans-mural inflammatory lesions. While the etiology and pathogenic mechanisms underlying IBD remain largely elusive, the development of IBD results from an extremely complex interaction among genetics, environments, microbial factors and autoimmune responses, eventually leading to chronic inflammation and tissue destruction in the gastrointestinal tract 2 . Despite enormous efforts in optimizing the existing drugs and developing new drugs in recent years, a large portion of IBD patients are still not responsive to medical treatment. This is largely due to the fact that the current therapeutic drugs, such as corticosteroids, nonsteroidal anti-inflammatory drug (NSAIDs) and anti-tumor necrosis factor (TNF) agents, have a very selective action and routinely aim for one therapeutic objective. Consequently, stem cell therapy has been emerging as a new paradigm for IBD treatment, largely owing to their multifaceted biological functions.
Compared with other sources of stem cells, mesenchymal stem cells (MSCs) exhibit many favorable characteristics including easy accessibility, no ethical issues and immunological compatibility 3 . Of importance, MSC transplantation is considered safe and has been widely tested in clinical trials of cardiovascular, neurological, and immunological diseases with encouraging results 4 . Indeed, MSC-based therapy has been appearing as a novel approach targeting the multiple pathological processes involved in IBD, which aims to replace damaged tissues, inhibit inflammation and suppress fibrosis 5, 6 . In 2005, García-Olmo et al. reported the first phase I clinical trial on eight complex fistulas in five CD patients by using adipose tissue-derived MSCs (AT-MSCs) with positive results 7 . From then on, numerous studies have been initiated to investigate the therapeutic effects and biological functions of MSCs derived from diverse sources including bone marrow, adipose tissue, umbilical cord, gingiva and human embryonic stem cells 5, [8] [9] [10] . In colitis models, MSCs have been observed to differentiate into cells that can repair intestinal damage and restore the integrity of the epithelial barrier 11 . Moreover, MSCs display anti-inflammatory and immunomodulatory effects, especially immunosuppressive properties by interacting with various immunoregulatory cells. In particular, MSCs produce a wide range of factors that have been implicated in immunomodulating effects, such as indoleamine 2,3dioxygenase 12 , interleukin (IL)-10 13 , prostaglandin E2 (PGE2) , 14, 15 transforming growth factor (TGF)-b 1 16 and nitric oxide. 17 Among them, PGE2 has been shown to modulate immune response via its action on various immune cells. For instance, PGE2 not only plays an active role in the maturation of dendritic cells, but also up-regulates the production of immunosuppressive IL-10 in dendritic cells 18 . In addition, PGE2 inhibits IL-2 production and T-helper cell proliferation, whereas promotes the production of regulatory T-cells 15, 19 .
MSC therapy for IBD represents a promising strategy. However, for the ultimate application of MSCs in a clinical setting, there are still many hurdles for us to overcome. For instance, despite enormous potential, many animal studies reported low levels of MSC recruitment and persistence in vivo 20 . Therefore, methods for enhancing the survival and anti-inflammatory effects of MSCs are urgently needed to improve their clinical efficacy. Previous studies from both our group and others demonstrated that priming MSCs with defined preconditioning media improved cell survival, migration, differentiation capacities and secretory function of MSCs [21] [22] [23] [24] [25] . Given that the therapeutic effects of MSCs on IBD are largely associated with their secretory function which contributes to immune and inflammation modulation, we reasoned that the preconditioning strategy might impact on the therapeutic effects of MSCs on IBD treatment. Thus, we undertook the present study to evaluate the effect of preconditioning on the immunoregulatory function of MSCs and their therapeutic efficacy in treating IBD.
Materials and Methods

Cell Culture
Human umbilical cord mesenchymal stem cells (hUCMSCs) were purchased from ATCC (PCS-500-010, Manassas, VA, USA). Cells were cultured at 37 C, 5% CO 2 in minimal essential medium alpha, with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were passaged every 2-3 days when they reached 70-80% confluence. Passages between 5 to 12 were used in this study. Jurkat and HCT116 (purchased from Institute of Biochemistry and Cell Biology, CAS, Shanghai, China) cells were cultured with RPMI-1640, 10% FBS and 1% penicillin-streptomycin. Cells were passaged when they reached 70-80% confluence.
Preconditioning and Deconditioning
The hUCMSCs were seeded at 6Â10 5 cells per 75 cm 2 flask and b-fibroblast growth factor (FGF) (10 ng/ml) (PeproTech, Rocky Hill, NJ, USA) and all-trans-retinoic acid (ATRA, 10 À7 M) (Sigma, St. Louis, MO, USA) were added to culture medium 24 hours later. After another 24 hours, cells were rinsed with phosphate-buffered saline (PBS) and cultured with modified neuronal medium (MNM) for preconditioning (primed-hUCMSCs) for another 24 hours 23 . The MNM was then washed out and replaced with a-minimum essential medium (MEM), cells were allowed to grow for another 2 days (deconditioning phase) and indicated as deconditioned MSCs (De-hUCMSCs). For re-preconditioning, the De-hUCMSCs were cultured in MNM for another 24 hours. To collect conditional medium, hUCMSCs or De-hUCMSCs were washed with PBS three times, and 10 ml serum-free a-MEM per 1.5Â10 6 cells was added. The medium was collected 24 hours later, and filtered as conditional medium.
MTT
MTT assay (Sigma-Aldrich, St. Louis, MO, USA) was used to evaluate cell viability. Cells were seeded in 96-well plates at a density of 5000 cells per well. Cells were rinsed with PBS 24 h post seeding and 100 ml conditional medium was added. After culture for the indicated period, MTT was added to and the optical density (OD) value was detected at 570 nm as suggested by the vendor.
Jurkat and hUCMSCs/De-hUCMSCs Co-culture
The 5Â10 6 Jurkat cells were seeded in 1640 medium with 10% FBS and 1% P/S, 25 mg/ml Phorbol 12-myristate 13acetate (PMA) and 1 mM ionomycin were applied to activate Jurkat for 24 hours. The 4Â10 5 hUCMSCs or De-hUCMSCs per well were seeded in six-well plates. After 24 h, hUCMSCs/De-hUCMSCs were washed with PBS twice. Activated Jurkat cells were directly seeded on hUCMSCs/ De-hUCMSCs (1Â10 6 per well). After 48 h, Jurkat cells were transferred to a 96-well plate (100 ml per well), 25 ml
) was then added, and OD values were read at 490 nm.
HCT116 Treated with Conditional Media
The 5Â10 5 HCT116 cultured in Roswell Park Memorial Institute (RPMI)-1640 medium was washed with PBS and cultured in serum-deprived media with 100 mg/ml TNF-a for 24 hours. Conditional media from hUCMSCs or De-hUCMSCs was then added into treated HCT-116 for 24 h. Cell proliferation was measured by MTT assay.
Flow Cytometry
Cells were collected and washed with PBS, then re-suspended in the staining buffer (PBS with 1% bovine serum albumin; BSA) at a concentration of 5Â10 5 cells/100 ml. Fluoresceinconjugated antibodies were added to the cell suspension and incubated at room temperature for 30 min in the dark. Cells were washed with PBS once, re-suspended in 400 ml of staining buffer and analyzed by flow cytometry. Annexin V-APC/ PI Kit was used to evaluate cell apoptosis. Experiments were carried out following the manufacturer's instructions. Fluorescent signals were detected with a flow cytometer (LSR Fortessa Cell Analyzer, BD, CA, USA).
Semi-Quantitative Polymerase Chain Reaction (PCR) and Quantitative Real-Time (qRT) PCR
Total RNA was isolated using TRIZOL Reagent (Invitrogen, Waltham, MA, USA), 1-5 mg total RNA were used for reverse transcription, first-strand complementary DNA synthesis was performed using oligd(T) 18 and M-MLV enzyme (Promega, Madison, WI, USA). A PRISM PCR system was applied to amplify target genes (thermal cycling program: 1: 94 C 4 min; 2: 94 C 30 s; 3: 55 C 30 s; 5: 72 C 30 s; 4: 72 C 10 min; 2-5 was repeated 30-35 cycles). PCR products were separated by agarose gel electrophoresis and analyzed by detection system software version 2.2.1 (Applied Biosystems, Foster City, CA, USA). For qRT-PCR, the levels of mRNA were measured by real-time PCR (Applied Biosystems) using SYBR Green Master Mix (Applied Biosystems). The total amount of mRNA was normalized to endogenous glyceraldehyde 3-phosphate dehydrogenase mRNA. The sequences of the primers were shown in Supplementary Table 1 .
PCR Array
Total RNA was isolated using the RNeasy mini kit according to manufacturer's instructions (Life Technologies, Carlsbad, CA, USA). The quantity of RNA was determined by spectrophotometer at 260 nm and the OD 260/280 ratio was measured to determine RNA quality. Then 1 mg total RNA of each sample was transcribed into cDNA using RT 2 First Strand Kit (Qiagen, Hilden, Germany). Real-time PCR array analysis was performed according to the manufacturer's protocol with the RT 2 Real-Time SYBR green PCR Master Mix on Applied Biosystems' 7500 Fast Real-Time PCR System. Expression of 84 genes was analyzed using the MSC (PAHS-082C) RT 2 profiler PCR array. Data were normalized using multiple housekeeping genes and analyzed by comparing 2 ÀDCt of the normalized data. Fold changes were calculated relative to the untreated MSCs. An arbitrary cut-off of >1.8-fold change was used to identify genes that were differentially expressed between samples.
Western Blot
Cells or tissues were lysed at 4 C using radioimmunoprecipitation assay lysis RIPA (Thermofisher, Waltham, MA, USA) buffer with a protease inhibitor cocktail for 30 min. Supernatants were collected and the concentrations of protein were measured by Bradford protein assay system (Bio-Rad, Hercules, CA, USA). Proteins were incubated with primary antibodies overnight at 4 C, then washed and incubated with horseradish peroxidase-conjugated secondary antibodies diluted 1:10,000 in 2% milk tris-buffered saline tween-20. Antibodies used in the western blot are listed in Supplementary Table 2 . The membranes were washed, protein bands were detected by enhanced chemiluminescence reagent (Amersham, Little Chalfont, UK) and SuperRX-film (Fuji Medical, Stamford, CT, USA). For quantification, densitometry in ImageJ was applied to quantify the relative intensities of bands.
Enzyme-Linked Immunosorbent Assay
2Â10 5 hUCMSCs or 1.5Â10 5 De-hUCMSCs were seeded in one well of the six-well plates. After 24 hours, cells were rinsed with PBS and 1 ml serum-free a-MEM medium (Thermofisher, Waltham, MA, USA) was added. Medium was collected 48 h later and used immediately or stored at À80 C. Colons were homogenized in PBS with 0.5% 100x Triton (Sigma, St. Louis, MO, USA) and protease inhibitor cocktail. Lysates were incubated at 4 C for 30 mins, followed by 14,000 rpm centrifuge at 4 C. Supernatant was collected and protein concentration was measured by the Bradford protein assay system (Bio-Rad). The enzymelinked immunosorbent assay (ELISA) kits used were Mouse IL-6, IL-10 ELISA Kits (ThermoFisher Scientific, Waltham, MA, USA; EM2IL6, EM2IL10, EMTNFA), Mouse IL-17a ELISA kit (Invitrogen, Carlsbad, CA, USA; KMC3021), Prostaglandin E 2 EIA Kit-Monoclonal (Cayman, Ann Arbor, MI, USA; 514010) and Human IL-2, IL-10 (ThermoFisher Scientific; EH2IL2, EHIL10).
Dextran Sulfate Sodium-induced IBD Mouse Model
Mature female C57 mice (weight 19-21 g, purchased from Laboratory Animal Services Center of the Chinese University of Hong Kong) were used in this study. All animal experiments were conducted in accordance with the guidelines and regulations on animal experimentation of the Chinese University of Hong Kong and approved by the Animal Ethnics Committee of the University (15-225-MIS). Mice were fed with 1.5% dextran sulfate sodium (DSS) (w/v) in drinking water (ddH 2 O) for 6 consecutive days to establish the model. Weights of the mice were measured every day throughout the whole experiment. Mice were randomly divided into three groups, PBS group; hUCMSCs group; and De-hUCMSCs group. On the 2nd and 6th day of DSS feeding, 100 ml of PBS or 2Â10 6 hUCMSCs or De-hUCMSCs in 100 ml PBS were intraperitoneally (IP) injected into each mouse. At different time points, mice were sacrificed with CO 2 , and colons and spleens were collected for further studies.
Primary Culture of Splenocytes
C57 mice were fed with 1.5% DSS in drinking water for 6 consecutive days to activate the inflammatory response. Mice were sacrificed and spleens were collected. A syringe with a 24G needle was applied to insert PBS into the spleens, and washed till spleens turned white. The solution was collected and centrifuged at 500 g at room temperature for 5 min. Red blood cells were lysed with ammonium chloride (0.75%, w/v), and left cells were rinsed by PBS three times and re-suspended in RPMI 1640 with 10% FBS. After collection, splenocytes were seeded on either hUCMSCs or De-hUCMSCs at the ratio of 4:1.
Disease Activity Index
The disease activity index (DAI) of IBD was assessed according to a previously established method 26 . Briefly, DAI is the summation of three parameters (0-4 score for each): body weight loss, stool consistency and occult bleeding. Weight loss score (0: <5%; 1: 5-10%; 2: 10-15%; 3: 15-20%; 4: >20%), stool consistency score (0: normal; 2: loose; 4: diarrhea), occult bleeding was detected by a Hemoccult II SENSA kit (Beckman, Brea, CA, USA) and scored according to the blue color intensity.
Histology Score
Histological analysis of IBD severity was based on the following parameters as described in a previously study 27 : (1) epithelial damage (0: none; 1: minimal loss of goblet cells; 2: massive loss of goblet cells; 3: slight loss of crypts; and 4: massive loss of crypts), and (2) infiltration (0: none; 1: crypt base infiltration; 2: mucosa infiltration; 3: severe mucosa infiltration and edema; and 4: submucosa infiltration).
Hematoxylin and Eosin (H&E) Staining
Paraffin-embedded colons were prepared in 6-mm sections, de-paraffinized using xylene and rehydrated through gradient alcohol (100% Â 2, 95% Â 2, 80% Â 1, 70% Â 1, water Â 1, 90 s per step with shaking). The frozen sections (6 mm) were firstly washed with PBS for 5 min, then dipped into water for 2 min. After rehydration, sections were stained with hematoxylin for 5 min, and differentiated in acid ethanol for 3 min. Then the sections were washed in running tap water for 2 min, blued in tap water for 10 min and stained in eosin Y solution for 1-2 min. 95% Â 2 plus 100% Â 2 alcohol was added for dehydration, cleared with xylene twice and finally mounted with histological mounting medium.
Immunofluorescence Staining
Sections were rehydrated as described for H&E staining, then rinsed with PBS twice. Antigen retrieval was carried out by soaking and heating samples to 95 C in antigenrefined buffer (pH 9) and cooled to room temperature. Slides were washed in PBS for three times, blocked with 2% donkey serum in PBS with 0.1% Triton for an hour. Primary antibody incubation was carried out at room temperature for 2 h, or 4 C overnight, then rinsed in PBS three times. A secondary antibody was added to sections and incubated at room temperature for 1 h. Samples were rinsed in PBS three times and mounted with 4',6-diamidino-2-phenylindole (DAPI)-containing mounting medium. Results were collected by fluorescent microscope (Nikon, Tokyo, Japan; 80i) and signals were indicated as a percentage of positive stained cells. Images were evaluated in five different fields, and >100 cells were evaluated for each slide. Primary and secondary antibodies are listed in Supplementary Table 2 .
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL)
Sections were rehydrated as described for H&E staining. TUNEL staining was carried out using an in-situ cell death detection kit (Roche, Basel, Switzerland), then mounted with DAPI-containing medium.
Statistical Analysis
All experiments were repeated at least three times, data are presented as mean + SEM. A Student's t test was applied to calculate the differences between two groups while a oneway analysis of variance (ANOVA) was applied for comparison among three groups, and post-hoc analyses were performed with Newman-Keuls multiple comparison test. Statistically significant was considered as P < 0.05 (*indicates P < 0.05, **indicates P < 0.01 and ***indicates P < 0.001). Statistical calculations were performed with GraphPad Prism software.
Results
Preconditioning Enhances Cell Survival and Alters the Secretory Function of MSCs
In this study, we decided to use hUCMSCs due to the fact that hUCMSCs have many advantages compared with human bone marrow-derived MSCs (hBMSCs) 28 . In particular, hUCMSCs have been extensively evaluated for treating IBD in both preclinical and clinical studies 15, [29] [30] [31] . To affirm the effect of preconditioning on hUCMSCs, we employed the protocol previously used for BMSCs 22, 23 . When hUCMSCs were subjected to all-trans-retinoic acid followed by MNM, they underwent dramatic morphological changes. Withdrawal of MNM rapidly reverted the primed MSCs back to mesenchymal morphology (deconditioned MSCs, De-hUCMSCs) ( Fig. 1A ). We then compared the cell-surface markers between De-hUCMSCs and their un-manipulated counterparts at passage 1 to 2, and found that there was no difference in CD marker expression between De-hUCMSCs and hUCMSCs ( Fig. S1A and B) , indicating that the preconditioning procedure does not change hUCMSC phenotype. To further determine whether the De-hUCMSCs are distinctive from the un-manipulated hUCMSCs, we first evaluated their proliferative capacity using MTT assay. Our result showed that while De-hUCMSCs grew faster at day 1, the growth rate slowed down on the following dates compared with hUCMSCs ( Fig. 1B) . We then determined the apoptotic response of hUCMSCs and De-hUCMSCs when challenged with hydrogen peroxide (H 2 O 2 ). Under the stress of 500 mM H 2 O 2 , De-hUCMSCs showed much higher resistance to apoptotic stimuli compared with hUCMSCs ( Fig. 1C) .
To further characterize the molecular identities of De-hUCMSCs, we used a focused real-time PCR array encompassing 84 genes associated with MSC identity (PAHS-082C). As shown in Fig. S3A , 13/84 MSC-related genes (15.5%) were differentially expressed between hUCMSCs and De-hUCMSCs. Among them, various transcripts that are associated with MSC secretion, were globally changed. For instance, the expression levels of BMP2, BMP6, TGFB3 were significantly upregulated in De-hUCMSCs, indicting preconditioning alters the secretory function of MSCs ( Fig. S2A and B ). In addition, we also compared the expression levels of various genes involved in cellular stress response and inflammation regulation. Interestingly, several cytokines involved in inflammation modulation were differentially expressed between hUCMSCs and De-hUCMSCs ( Fig. S2B ). Taken together, these data suggest that preconditioning enhances cell survival and alters the secretory function of MSCs.
De-hUCMSCs Ameliorate Colitis More Profoundly than hUCMSCs in a DSS-induced IBD Mouse Model
To test the potential therapeutic effect of hUCMSCs/De-hUCMSCs on IBD, we used a DSS-induced mouse model. In this model, with 1.5% (w/v) DSS, mice presented the most evident clinical signs of colitis from day 5 to day 8, along with a significant weight loss that peaked from day 7 to day 10. Thus, we decided to administer hUCMSCs/De-hUCMSCs twice on day 2 and day 6 ( Fig. 2A) . Our results showed that while hUCMSC-treated mice exhibited a mild reduction in weight loss and faster body weight recovery compared with PBS-treated mice, De-hUCMSCs demonstrated a more pronounced effect on reduction of weight loss and faster weight recovery from day 8 to 12 (Fig. 2B) . In order to further monitor the effects of De-hUCMSCs/ hUCMSCs on IBD clinical symptoms, the DAI was scored daily with three parameters: weight loss, stool consistency and occult bleeding. In hUCMSC-treated mice, the DAI was only significantly reduced on day 8 and day 12, as compared with PBS-treated mice. However, in De-hUCMSC-treated mice, the DAI was more consistently and markedly decreased during the recovery phase (Fig. 2C) .
To further investigate the protective effects of hUCMSCs/De-hUCMSCs on DSS-induced IBD, colon tissues were collected at day 5, 8 and 12 for histopathological examination in different treatment groups ( Fig. 2A ). We did not find any significant difference in colon length among different treatment groups (Fig. S3A ). However, histopathological examination of the colon sections in the distal and proximal tracts showed that the preconditioning significantly reduced the extension and the severity of the inflamed area and the infiltration of inflammatory cells, as compared with PBS or hUCMSC-treated mice (Fig. 2D, E, Fig. 3A and Fig.  S3B ). H&E staining indicated that De-hUCMSCs effectively reduced epithelial damage while hUCMSCs showed relatively mild protection. On day 8, while most of the crypts were damaged in the PBS-treated group, crypt structures were largely preserved in both hUCMSC and De-hUCMSC-treated colons with protective effects being more pronounced in De-hUCMSC-treated mice ( Fig. 2D and Fig.  S3B ). A quantitative evaluation of histological damage was performed, and the histological score confirmed that De-hUCMSC treatment significantly reduced the intestinal damage, whereas hUCMSCs did not have this effect (Fig.  2E ). In addition, we found that neutrophil infiltration was more remarkably suppressed in De-hUCMSC-treated mice than hUCMSC-treated mice (Fig. 3A) . As tight junction proteins play an important role in epithelial barrier function and intestinal homeostasis during IBD onset and development, we evaluated the expression of tight junction proteins Occludin-1 and ZO-1 to assess the integrity of epithelial barrier function. Our results showed that the expression levels of Occludin-1 and ZO-1 were dramatically increased in both hUCMSC and De-hUCMSC-treated colons compared with PBS-treated colons on day 8, which represents the most severe stage of intestinal injury in the DSS model. However, the effect of De-hUCMSCs was more significant (Fig. 3B  and Fig. S3C ). Altogether, both hUCMSCs and De-hUCMSCs alleviate the DSS-induced colitis, whereas De-hUCMSCs are more effective.
De-hUCMSCs Suppress the Apoptotic Response and Activate the ERK Pathway in the Colon
Having established that De-hUCMSCs elicited better protective effects in DSS-induced colitis, we proceeded to determine the underlying cellular and molecular mechanisms involved in the protective function of De-hUCMSCs. During IBD progression, epithelial cell damage is largely induced by TNF-a-mediated apoptosis, which is closely associated with disease progression and severity. Thus, we determined the apoptotic response by TUNEL staining in control or hUCMSCs/De-hUCMSCs-treated colons. As shown in Fig.  4A , a large number of apoptotic cells were present in the IBD colon on day 5 and day 8. Significantly, while hUCMSCs had no effect on reducing the number of apoptotic cells, De-hUCMSCs dramatically suppressed apoptotic response upon DSS treatment on day 5, indicating De-hUCMSCs probably activated the anti-apoptotic pathway. To further elucidate the molecular mechanisms underlying the anti-apoptotic effect of De-hUCMSCs, a western blot was performed using colon samples collected on day 5, day 8 and day 12, which represented the different stages of the inflammatory process. In consistence with the TUNEL staining, the expression levels of cleaved caspase-3 and p21 were significantly reduced in De-hUCMSC-treated colons but not hUCMSC-treated colons on day 5 and day8 (Fig. 4B) , confirming that De-hUCMSC treatment suppresses the apoptotic response. Interestingly, our western blot result revealed that the expression of p-ERK was significantly increased in De-hUCMSC-treated mice compared with PBS-treated mice, whereas hUCMSC treatment did not have this effect (Fig. 5A ). We did not find any significant change in p65 or the c-Jun N-terminal kinase (JNK) pathway, which are both implicated in the regulation of the apoptotic response in the intestine (Fig. 5A and Fig. S4A ). Since activation of the ERK pathway plays a critical role in the survival of intestinal epithelial cells 32, 33 , it is plausible that the pro-survival effect of De-hUCMSCs is mediated by the ERK pathway. However, it should be noted that the activation of p-ERK could only be detected on day 5, but not on day 8 and day 12 (Fig. S4A) , indicating that the anti-apoptotic effect of De-hUCMSCs was mainly executed in the early stages of IBD.
De-hUCMSCs Suppress Early Immune Response During Colitis Progression
In order to understand the role of hUCMSCs/De-hUCMSCs in intestinal epithelial protection, we first determined the paracrine effect of stem cells on intestinal epithelial cells using HCT116. We mimicked an inflammatory environment by treating HCT116 with TNF-a and evaluated whether hUCMSCs/De-hUCMSCs would protect HCT116 from TNF-a-induced apoptosis. Our MTT assay results showed that while hUCMSCs did not have any effect, De-hUCMSCs promoted HCT116 cell survival slightly in response to TNFa treatment (Fig. 5B ). However, neither hUCMSCs nor De-hUCMSCs had any effect on TNFa-induced apoptosis in HCT116 cells (Fig. 5C ). These results suggest that hUCMSCs/De-hUCMSCs might not directly affect epithelial cell survival. During colitis, ulcerated lesions are accompanied by a prominent infiltration of inflammatory cells, including T-lymphocytes, macrophages, and neutrophils. Furthermore, mechanisms underlying recruiting and activating inflammatory cells are believed to involve a complex interplay of inflammatory mediators such as chemokines and cytokines. One component of the immune infiltration is CD3 þ T-lymphocytes which are critical effectors of the mucosal immune activation. Our western blot analysis in DSS-induced colon samples showed that both hUCMSC and De-hUCMSC treatment significantly decreased the expression of CD3 on day 5 (Fig. 5D ), while this effect was more pronounced in De-hUCMSC-treated IBD colons. However, this effect diminished at the recovery stage of inflammation (data not shown), indicating hUCMSCs/De-hUCMSCs suppresses early but not late immune response.
De-hUCMSCs Modulate T-cell-Mediated Immune Response Through PGE2 Secretion
As HCT116 co-culture experiments indicate that the protective effect of De-hUCMSCs on DSS-treated colitis is not likely attributable to the direct interaction between stem cells and epithelial cells, we further explored the involvement of T-lymphocytes based on our finding that De-hUCMSCs suppressed the expression of CD3 during early stage of inflammation. We first co-cultured hUCMSCs/De-hUCMSCs with PMA/ionomycin-activated Jurkat cells and evaluated the effect of stem cells on T-cell proliferation by MTS assay. As shown in Fig. 6A , both hUCMSCs and De-hUCMSCs significantly suppressed Jurkat cell viability, whereas the effect of De-hUCMSCs was stronger. Given that PGE2 is a very important inflammatory regulator involved in the maintenance of immune homeostasis, and MSCs have been demonstrated to suppress immune responses via PGE2 secretion in various immune and inflammatory diseases [34] [35] [36] , we reasoned that the enhanced therapeutic effect of De-hUCMSCs might be due to increased secretion of PGE2. Indeed, we found that De-hUCMSCs secreted a higher level of PGE2 compared with hUCMSCs ( Fig. 6B ). Thus, we went further to investigate whether the enhanced suppressive effect of De-hUCMSCs was mediated by increased PGE2 secretion. Strikingly, our results showed that PGE2 inhibitors NS-398 and indomethacin reversed the inhibitory effects of hUCMSCs/De-hUCMSCs on Jurkat proliferation (Fig. 6C ). In addition, NS-398 completely reversed the differences between hUCMSCs and De-hUCMSCs in suppressing T-cell activation, indicating this effect was mediated by PGE2 ( Fig. 6C) . Besides T-cell viability, we also determined whether hUCMSCs/De-hUCMSCs were able to modulate the immunoregulatory function of T-lymphocytes. We showed that both hUCMSCs/De-hUCMSCs dramatically suppressed the mRNA expression of proinflammatory cytokines, such as TNF-a and IL-2, in activated Jurkat cells (Fig. 6D ). Since IL-10 is an anti-inflammatory cytokine and immunosuppressive factor, which has been implicated in the immune modulatory function of MSCs in IBD treatment 13, 37 , we also determined the effect of hUCMSCs/De-hUCMSCs on IL-10 expression. Interestingly, both hUCMSCs and De-hUCMSCs co-incubation significantly increased the mRNA expression of IL-10 in Jurkat, whereas the effect of De-hUCMSCs was more prominent (Fig. 6D ). This effect was further confirmed by ELISA analysis showing that De-hUCMSCs dramatically increased the secretion of IL-10 in activated Jurkat. Furthermore, suppression of PGE2 by NS-398 completely reversed the promoting effect of De-hUCMSCs on IL-10 secretion (Fig. 6E) , further pinpointing the critical role of PGE2 in mediating the immune modulatory effect of De-hUCMSCs. To confirm the results from Jurkat cells, we isolated mouse splenocytes in IBD mice and co-cultured them with either hUCMSCs or De-hUCMSCs for 24 h. Consistent with the Jurkat data, both hUCMSCs and De-hUCMSCs significantly decreased CD3 þ splenocytes, whereas the effect of De-hUCMSCs was stronger. This effect was completely reversed by the pre-treatment with PGE2 inhibitors (Fig. 6F ). Collectively, these results clearly indicate that hUCMSCs/ De-hUCMSCs suppress T-lymphocyte viability and modulate their immunoregulatory function through secretion of PGE2.
Discussion
The etiologic and pathologic process of human IBD is multifactorial, but a critical part of this disease is the disrupted homeostasis of immune responses 38 . MSCs produce large amount of soluble or membrane-bound factors, which are implicated in the modulation of immune responses through interaction with various immune cells 39 . Promisingly, MSCs have been observed to exert potent immunomodulatory and anti-inflammatory effects in different IBD models 40 . In the present study, we introduce a novel strategy to improve the efficacy of MSC-based cellular therapy for IBD treatment. We show that preconditioning improves the therapeutic efficacy of hUCMSCs via a prostaglandin E 2 -mediated immunosuppressive effect in IBD treatment .
DSS-induced colitis is the most commonly used animal model for the study of human IBD. In our study, by oral feeding of 1.5% (w/v) DSS for 6 days, we have successfully established IBD mouse model which recapitulates the early, severe and recovery stage of IBD pathology. Compared with hUCMSCs, De-hUCMSCs appeared to offer evident therapeutic advantages in IBD treatment. Firstly, De-hUCMSCs ameliorated colitis manifestation more significantly than hUCMSCs. De-hUCMSC treatment led to a more prominent reduction in body weight loss and better recovery ( Fig. 2B  and C) . Secondly, De-hUCMSCs transplantation resulted in a more profound improvement in DSS-induced colitis pathology, that is, ulceration, dilation, damage of the crypts and infiltration of inflammatory cells were significantly alleviated in De-hUCMSC-treated mouse colon as indicated by a decreased DAI score (Fig. 2D, 2E, and Fig. 3A) . Thirdly, the expression of tight junction proteins, such as ZO-1 and Occludin-1, was better conserved in De-hUCMSC-treated colons ( Fig. 3B and Fig. S4C ), indicating that De-hUCMSCs are more effective than hUCMSCs in protecting the epithelial barrier function. Collectively, our results demonstrate that in comparison with hUCMSCs, De-hUCMSCs are more effective in reducing clinical and pathological signs of colitis, which are highly relevant in view of the use of MSCs for the treatment of IBD patients. Increased apoptosis of epithelial crypt cells and epithelial barrier cells generally occurs in UC and CD 41, 42 . In our study, we found that De-hUCMSCs significantly suppressed apoptosis in IBD colons on day 5 (Fig. 4) . The anti-apoptosis function of De-hUCMSCs, to some extent, explains the therapeutic effects displayed by De-hUCMSCs. De-hUCMSCs elicit their protective role by dampening the apoptotic response, which in turn alleviates inflammatory response and epithelial damage. Of note, numerous studies have suggested that the TNF-mediated pathways play key roles in inducing apoptosis in epithelial crypts and barrier 43 . The importance of TNF in disease pathogenesis is underlined by the prominent clinical improvement induced by anti-TNF antibodies 44 . However, whereas it seems likely that neutralization of soluble and membrane-bound TNF might be a key mechanism, the potential of the anti-TNF antibodies to induce lymphocyte/monocyte apoptosis in CD has been considered an additional important mechanism 45 . Moreover, other potential mode of actions includes induction of the anti-inflammatory cytokines IL-10 or TGF-b via retrograde signaling or induction of a certain subset of regulatory T-cells 46 . Thus, it remains unclear whether the effect of anti-TNF on mucosal healing is related to reduced epithelial apoptosis, and whether other cellular components in the injured tissues contribute to the healing effects. In this report, we showed that De-hUCMSCs did not affect epithelial cell survival but rather suppressed T-cell activation directly ( Fig. 5D and Fig. 6 ). Our results are consistent with a scenario in which the proinflammatory cytokines secreted by T-lymphocytes play key roles in inducing programmed cell death in epithelial cells. Thus, it is plausible that the anti-inflammatory and immunomodulatory effect of De-hUCMSCs is mainly attributed to the suppression of T-lymphocyte activation and subsequent immunemediated apoptosis.
Although the mechanisms by which MSCs regulate the immune response during the pathological processes of IBD are still under intensive investigation, it is well established that MSCs are capable of suppressing proliferation, maturation, and activation of immune cells through secretion of assorted soluble factors [12] [13] [14] [15] [16] [17] . One interesting finding from our study is that De-hUCMSCs suppress the proliferation and activation of T-lymphocytes via the paracrine secretion of PGE2 . The role of PGE2 in mediating the therapeutic effects of MSCs has been illustrated in IBD mouse models 15 . Using both DSS-and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis models, Kim et al., recently showed that PGE2 secretion from hUCMSCs shifted the immune balance from T-helper 1 to T-helper 2 responses, along with an increment in T-regulator cell population. Strikingly, inhibition of PGE2 synthesis almost completely diminished the immunosuppressive and therapeutic effects of MSCs, indicating the pivotal role of PGE2 in MSC function 15 . In our study, we found that the preconditioning strategy remarkably increased the PGE2 secretion in hUCMSCs (Fig. 6B ). Suppression of PGE2 secretion in De-hUCMSCs completely abrogated the inhibitory effect of De-hUCMSCs on T-cell proliferation ( Fig. 6C and 6F) , implying that the crosstalk between De-hUCMSCs and T-cells was mediated by PGE2. Indeed, we demonstrated that co-incubation with hUCMSCs/De-hUCMSCs dramatically decreased the secretion of TNF-a and IL-2 in Jurkat cells ( Fig. 6D and Fig.  S4B ). In addition, De-hUCMSCs but not hUCMSCs markedly induced the secretion of anti-inflammatory cytokine IL-10 in Jurkat cells (Fig. 6E ). It should be noted that since our DSS model induces mild colitis with a relative long induction phase and a very short acute phase, both hUCMSC and De-hUCMSC treatment only mildly affect cytokine production in colitis colon and plasma (Fig. S4C) . Taken together, we suggest that De-hUCMSCs elicit their enhanced protective role in IBD treatment via suppression of PGE2-mediated T-cell proliferation and activation, which subsequently reduces T-cell-mediated apoptotic response in intestinal epithelium. In view of the fact that PGE2 modulates the immune response via almost all kinds of immune cells, it is plausible that other immune cells are also involved in the enhanced therapeutic effects of De-hUCMSCs.
Collectively, we have demonstrated that hUCMSCs can be manipulated in vitro via preconditioning and deconditioning with enhanced immunosuppressive and therapeutic effects on treating IBD via increased secretion of PGE2. Given the critical role of PGE2 in regulating the immune response, it is conceivable that the preconditioning strategy might exhibit improved therapeutic efficacy in treating other autoimmune diseases, such as rheumatoid arthritis. With easy culture manipulation and a low tendency of tumor formation, the preconditioning strategy provides a feasible approach to enhance therapeutic efficacy for stem cellbased regenerative medicine.
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